组合型人工肾在尿毒症治疗中的应用

目的探讨组合型人工肾在尿毒症治疗中的临床疗效和安全性。方法对30例长期维持性血液透析患者采用组合型人工肾治疗（治疗组），并与单独血液透析治疗29例尿毒症患者（对照组）疗效进行对比研究，观察两组临床症状改善、血尿素氮（BUN）、肌酐（Cr）、中分子物质（MMS）清除及血常规变化情况。结果两组治疗后血BUN、Cr、血红蛋白含量、血白细胞计数、血小板计数均较治疗前明显改善（均P〈0．05），但两组间无明显差异（P〉0．05），治疗组MMS清除率（25．6％）及临床症状改善方面好于对照组（5．9％），组间比较差异有统计学意义（P〈0．05，P〈0．01）；两组均未发生严重不良事件。结论组合型人工肾能更好地清除体内中分子物质，明显改善患者临床症状，弥补了常规血液透析的不足。

Application of hybrid artificial kidney in the treatment of uremia

Objective To investigate the clinical efficacy and safety of hybrid artificial kidney in the treatment of patients with uremia.Methods 30 maintenance hemodialysis patients who were altered to be treated by hybrid artificial kidney(treatment group)were compared with 29 patients who were treated by hemodialysis only(control group).The amelioration of clinical symptom,remove of urea nitrogen(BUN),creatinine(Cr).Middle Molecular Substance(MMS)and variation of blood regular test were observed.Results BUN,Cr,haemoglobin level,leucocyte count and blood platelets count improved between after and before treatment(P ＜0.05),but there was no significant difference between the two groups(P ＞ 0.05).Clearance rate ofMMS(25.6%)and improvement of clinical symptoms in treatment group were better than those of control group(5.9%)and difference was statistically significant(P ＜0.05,P＜0.01).There was no serious adverse events in two groups.Conclusion Hybrid artificial kidney could remove molecular substances better and markedly improv clinical symptoms.It can make up for the shortcomings of conventional hemodialysis.